501
Human Insulin

We developed a soft mist inhaled human insulin for the treatment of type 1 and 2 diabetes. Clinical data based on our five Phase 1/2a studies demonstrated Aerami 501 has:

• Faster onset and similar profile versus lispro
• Intra and inter-subject variability similar to injections
• Minimal to no cough following inhalation

601
SHORT ACTING GLUCAGON LIKE PEPTIDE (GLP-1) ANALOG

We have formulated a rapid acting GLP-1 agonist, Aerami 601, for delivery via our smart inhaler prior to meals, to help type 2 diabetes (T2D) patients achieve a superior level of postprandial glucose control and avoid undesirable gastrointestinal side effects associated with injectable treatments. The smart inhaler enables pulsatile delivery of lower, flexible GLP-1 dosing.

• Flexible, convenient dosing
• Improved safety profile

Current treatment guidelines for T2D recommend GLP-1 starting from dual-therapy as one of the non-insulin medications to control both basal and postprandial hyperglycemia (hyperglycemia after meals). Approved therapies are mainly effective in controlling only the basal component, creating a significant unmet need for an alternative to address postprandial hyperglycemia.

701
Inhaled Parathyroid Hormone (PTH) for Hypoparathyroidism

We are developing an inhaled PTH, Aerami 701, to restore physiological levels of PTH by allowing for a convenient inhaled delivery of PTH in pulsatile treatments throughout the day.

Conventional treatments for hypoparathyroidism are inadequate and can lead to hypocalcemia, hypercalcemia and hypercalciuria (short-term); impaired renal function and extra skeletal calcifications (long-term). There is evidence that an ideal PTH drug delivery system that allows for pulsatile administration, such as an inhaled option, could better mimic the physiological tonic, circadian, and pulsatile profile of PTH leading to higher efficacy of the treatment. ² , ³

801
Inhaled Human Growth Hormone (hGH) for Growth Hormone Disorder

We are advancing an inhalable hGH, Aerami 801, that provides a better patient experience, encourages adherence and compliance leading to improved patient outcomes.

Poor adherence with daily injectable hGH is associated with reduced height velocity and impaired quality of life. ⁴